Systemic Lupus Erythematosus Market is anticipated to develop at a CAGR of 6.0% Forecast Period
Over the projection period of 2022–2030, the market for systemic lupus erythematosus is
anticipated to develop at a CAGR of 6.0%.
Systemic lupus erythematosus (SLE), generally referred to
as lupus, is a complicated, long-term autoimmune condition that causes
inflammation of body tissues. Fatigue, fever, skin rashes, joint discomfort,
malaise, and a brief loss of cognitive function are a few of the illness'
typical symptoms. These symptoms and indicators can differ from person to
person.
Download
Request for Sample@ https://www.xresearch.biz/request-sample-pages/systemic-lupus-erythematosus-market
The condition affects the connective tissues that give
the body's many organs and structures, including the kidneys, skin, joints,
lungs, central nervous system, and blood-forming (hematopoietic) system,
strength and flexibility. A complicated genetic and hormonal foundation has
been found in a few investigations, despite the fact that the disease's primary
origin is still unknown. The disease mainly affects people between the ages of
25 and 45 and can range in severity from moderate to severe. It is more
prevalent in women. It is estimated that 5.0 million individuals worldwide have
some kind of lupus. The disease's treatments under development focus on a wide
range of areas.
GROWTH
DRIVERS:
The global systemic lupus erythematosus
market is primarily being driven by factors such as the rising
prevalence of autoimmune diseases worldwide, the increased awareness of lupus
and SLE treatments, the increasing arrival of key pipeline agents that promise
higher efficacy than the currently available therapies, the rapid introduction
of new biological therapies, and the escalating R&D investment in SLE
drugs.
In addition, factors like the high level of unmet needs
in the SLE market for therapies that can lower the use of corticosteroids and
improve patients' quality of life, the rising number of manufacturers making
significant efforts to develop biologics with higher efficacy, and the rising
number of large players entering the market with promising therapies are
anticipated to further propel the market's growth during the forecast period.
However, factors like Benlysta's low to moderate
effectiveness in treating patients with severe systemic lupus erythematosus
(SLE), including lupus nephritis, the lack of knowledge about the disease's
pathogenesis, and the use of off-label medications may limit the market's
growth to some extent during the forecast period.
SYSTEMIC LUPUS
ERYTHEMATOSUS MARKET SEGMENTATION:
By Drug Classes:
· NSAID
· Corticosteroids
· Antimalarials
· Immunosuppressants
· Biologics
By Route of
Administration:
· Oral
· Intravenous
· Subcutaneous
· Topical
By Distribution
Channel:
· Retail
Pharmacies
· Hospitals
· Online
Pharmacies
By Region:
· North
America
· Europe
· Asia
Pacific
· Latin
America
· Middle
East and Africa
KEY COMPANIES IN
SYSTEMIC LUPUS ERYTHEMATOSUS MARKET:
· Pfizer
· Novartis
· Bayer
· Amgen
Inc.
· Bristol-Myers
Squibb Company
· GlaxoSmithKline
PLC
· Immunomedics
Inc.
· Johnson
& Johnson
· MedImmune
LLC
· Merck
Serono GmbH
· Sanofi
SA
· Teva
Pharmaceutical Industries Ltd.
· UCB
SA
· F.
Hoffmann-La Roche Ltd.
· Hansa
Medical Ab
· Harbor
Biosciences
· Other
Players
Read
More Information: https://www.xresearch.biz/shop/systemic-lupus-erythematosus-market
About Us:-
xResearch is a market
research and consulting organization that uses unique data, expert analysis,
and new technologies to create trusted intelligence on industries. Our research
is focused on delivering an informed and impartial view on essential market
data of industry, and it is primarily driven by an in-depth study covering the
following parameters: Market Sizing and Forecasting, Market Segmentation, Competitive Analysis, Strategic Assessment and Business Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-618-4545
Comments
Post a Comment